EE9900537A - Karbotsükliline nukleosiidhemisulfaat ja selle kasutamine viirusinfektsioonide raviks - Google Patents

Karbotsükliline nukleosiidhemisulfaat ja selle kasutamine viirusinfektsioonide raviks

Info

Publication number
EE9900537A
EE9900537A EEP199900537A EEP9900537A EE9900537A EE 9900537 A EE9900537 A EE 9900537A EE P199900537 A EEP199900537 A EE P199900537A EE P9900537 A EEP9900537 A EE P9900537A EE 9900537 A EE9900537 A EE 9900537A
Authority
EE
Estonia
Prior art keywords
treatment
viral infections
carbocyclic nucleoside
hemisulfate
nucleoside hemisulfate
Prior art date
Application number
EEP199900537A
Other languages
English (en)
Inventor
Francis Jones Martin
Frederick Seager John
John Wallis Christopher
Couper Brodie Alastair
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10812407&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE9900537(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of EE9900537A publication Critical patent/EE9900537A/et
Publication of EE03924B1 publication Critical patent/EE03924B1/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
EEP199900537A 1997-05-17 1998-05-14 Karbotsükliline nukleosiidhemisulfaat ja selle kasutamine viirusinfektsioonide raviks EE03924B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9709945.1A GB9709945D0 (en) 1997-05-17 1997-05-17 A novel salt
PCT/EP1998/002835 WO1998052949A1 (en) 1997-05-17 1998-05-14 Carbocyclic nucleoside hemisulfate and its use in treating viral infections

Publications (2)

Publication Number Publication Date
EE9900537A true EE9900537A (et) 2000-06-15
EE03924B1 EE03924B1 (et) 2002-12-16

Family

ID=10812407

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP199900537A EE03924B1 (et) 1997-05-17 1998-05-14 Karbotsükliline nukleosiidhemisulfaat ja selle kasutamine viirusinfektsioonide raviks

Country Status (51)

Country Link
US (1) US6294540B1 (et)
EP (1) EP0983271B1 (et)
JP (2) JP3150711B2 (et)
KR (1) KR100521292B1 (et)
CN (2) CN1150194C (et)
AP (1) AP2009A (et)
AR (2) AR015668A1 (et)
AT (1) ATE259811T1 (et)
AU (1) AU739953B2 (et)
BG (1) BG64390B1 (et)
BR (1) BRPI9809126B8 (et)
CA (1) CA2289753C (et)
CO (1) CO4940435A1 (et)
DE (1) DE69821758T2 (et)
DK (1) DK0983271T3 (et)
DZ (1) DZ2493A1 (et)
EA (1) EA001809B1 (et)
EE (1) EE03924B1 (et)
EG (1) EG23836A (et)
ES (1) ES2214712T3 (et)
GB (3) GB9709945D0 (et)
GE (1) GEP20022680B (et)
HK (1) HK1024236A1 (et)
HN (1) HN1998000071A (et)
HR (1) HRP980265B1 (et)
HU (1) HU226563B1 (et)
ID (1) ID24910A (et)
IL (2) IL132793A0 (et)
IS (1) IS2207B (et)
JO (1) JO2032B1 (et)
MA (1) MA26498A1 (et)
MY (1) MY120151A (et)
NO (1) NO324731B1 (et)
NZ (2) NZ510622A (et)
OA (1) OA11304A (et)
PA (1) PA8451301A1 (et)
PE (1) PE78799A1 (et)
PL (1) PL189527B1 (et)
PT (1) PT983271E (et)
RS (1) RS49655B (et)
SA (1) SA98190179B1 (et)
SI (1) SI0983271T1 (et)
SK (1) SK285159B6 (et)
SV (1) SV1998000057A (et)
TN (1) TNSN98065A1 (et)
TR (1) TR199902810T2 (et)
TW (1) TW480259B (et)
UA (1) UA56231C2 (et)
UY (1) UY25004A1 (et)
WO (1) WO1998052949A1 (et)
ZA (2) ZA984085B (et)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9802472D0 (en) * 1998-02-06 1998-04-01 Glaxo Group Ltd Pharmaceutical compositions
HU226998B1 (en) * 2000-11-23 2010-04-28 Richter Gedeon Nyrt Desloratadine hemisulphate, process for the preparation thereof and pharmaceutical compositions containing the same
GB0320738D0 (en) 2003-09-04 2003-10-08 Glaxo Group Ltd Novel process
EP1905772A1 (en) * 2006-09-28 2008-04-02 Esteve Quimica, S.A. Process for the preparation of abacavir
JP5334852B2 (ja) * 2006-09-28 2013-11-06 エステヴェ キミカ， エス．エー． アバカビルの製造方法
EP2085397A1 (en) 2008-01-21 2009-08-05 Esteve Quimica, S.A. Crystalline form of abacavir
EP2218721A1 (en) * 2009-02-11 2010-08-18 LEK Pharmaceuticals d.d. Novel salts of sitagliptin
EP2305680A3 (en) 2009-09-30 2011-05-18 Aurobindo Pharma Limited Novel salts of (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol
DK3494972T3 (da) 2010-01-27 2024-01-29 Viiv Healthcare Co Kombinationer af dolutegravir og lamivudin til behandling af HIV-infektion
CN103282369A (zh) 2011-04-08 2013-09-04 劳乐斯实验室私营有限公司 抗逆转录病毒化合物与抗氧化酸的固体形式、其制备方法以及其药物组合物
EP2962693B1 (en) 2013-02-27 2019-01-09 Kyoto University Pharmaceutical composition comprising abacavir for the treatment of cancer
CN104788451A (zh) * 2014-01-21 2015-07-22 浙江九洲药业股份有限公司 一种阿巴卡韦的制备方法
CN105315280A (zh) * 2014-06-06 2016-02-10 上海迪赛诺化学制药有限公司 一种阿巴卡韦结晶体及其制备方法
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY104575A (en) * 1989-12-22 1994-04-30 The Wellcome Foundation Ltd Therapeutic nucleosides.
GB9417249D0 (en) * 1994-08-26 1994-10-19 Wellcome Found A novel salt
MY115461A (en) * 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
TR199802703T2 (xx) * 1996-06-25 1999-03-22 Glaxo Group Limited HIV tedavisinde Vx478, Zidov�din, ve/veya 1592U89 i�eren kombinasyonlar�n kullan�m�.

Also Published As

Publication number Publication date
JP2000327679A (ja) 2000-11-28
BR9809126A (pt) 2000-08-01
RS49655B (sr) 2007-09-21
PT983271E (pt) 2004-07-30
CN1263529A (zh) 2000-08-16
BG64390B1 (bg) 2004-12-30
HK1024236A1 (en) 2000-10-05
AR059120A2 (es) 2008-03-12
GB0010222D0 (en) 2000-06-14
BG103959A (en) 2000-12-29
EE03924B1 (et) 2002-12-16
IS5246A (is) 1999-11-11
WO1998052949A1 (en) 1998-11-26
DE69821758T2 (de) 2005-01-13
HRP980265B1 (en) 2004-10-31
YU59599A (et) 2002-08-12
KR100521292B1 (ko) 2005-10-17
CA2289753C (en) 2007-01-23
GB2340491A (en) 2000-02-23
CN1150194C (zh) 2004-05-19
HRP980265A2 (en) 1999-02-28
JP3150711B2 (ja) 2001-03-26
TNSN98065A1 (fr) 2005-03-15
TR199902810T2 (xx) 2000-02-21
GB2340491B (en) 2000-10-18
SA98190179B1 (ar) 2006-08-15
UY25004A1 (es) 2000-10-31
DK0983271T3 (da) 2004-05-10
AR015668A1 (es) 2001-05-16
ES2214712T3 (es) 2004-09-16
UA56231C2 (uk) 2003-05-15
EG23836A (en) 2007-10-02
TW480259B (en) 2002-03-21
ID24910A (id) 2000-08-31
GB2348202A (en) 2000-09-27
MA26498A1 (fr) 2004-12-20
CN1515572A (zh) 2004-07-28
SK156199A3 (en) 2000-07-11
EA001809B1 (ru) 2001-08-27
HUP0002754A3 (en) 2003-01-28
ZA984083B (en) 1999-11-15
NZ500865A (en) 2001-04-27
ZA984085B (en) 2000-01-26
EP0983271A1 (en) 2000-03-08
CA2289753A1 (en) 1998-11-26
BRPI9809126B8 (pt) 2021-07-06
AP2009A (en) 2009-06-26
HN1998000071A (es) 1999-03-19
GB9709945D0 (en) 1997-07-09
SI0983271T1 (en) 2004-06-30
NO995622L (no) 2000-01-14
JO2032B1 (en) 1999-05-15
HUP0002754A2 (hu) 2001-06-28
US6294540B1 (en) 2001-09-25
EP0983271B1 (en) 2004-02-18
IL132793A0 (en) 2001-03-19
NO324731B1 (no) 2007-12-03
GB2348202B (en) 2001-08-08
NZ510622A (en) 2002-04-26
AP9901688A0 (en) 1999-12-31
IL132793A (en) 2006-10-31
PA8451301A1 (es) 2000-05-24
EA199900944A1 (ru) 2000-06-26
KR20010012623A (ko) 2001-02-26
IS2207B (is) 2007-02-15
OA11304A (en) 2003-10-22
AU7765598A (en) 1998-12-11
DE69821758D1 (de) 2004-03-25
MY120151A (en) 2005-09-30
BRPI9809126B1 (pt) 2018-02-06
CN100408580C (zh) 2008-08-06
PL336888A1 (en) 2000-07-17
SV1998000057A (es) 1999-03-02
CO4940435A1 (es) 2000-07-24
PL189527B1 (pl) 2005-08-31
GEP20022680B (en) 2002-04-25
JP2000514096A (ja) 2000-10-24
DZ2493A1 (fr) 2004-06-20
GB9926839D0 (en) 2000-01-12
PE78799A1 (es) 1999-08-31
SK285159B6 (sk) 2006-07-07
AU739953B2 (en) 2001-10-25
ATE259811T1 (de) 2004-03-15
NO995622D0 (no) 1999-11-16
HU226563B1 (en) 2009-04-28

Similar Documents

Publication Publication Date Title
EE04452B1 (et) Farmatseutiliselt aktiivne morfolinool ja selle kasutamine
DK1021410T3 (da) Prostaglandinagonister og deres anvendelse til behandling af knogletilstande
NO991700D0 (no) Benzimidazol-2-karbamater for behandling av virusinfeksjoner og cancer
EE03924B1 (et) Karbotsükliline nukleosiidhemisulfaat ja selle kasutamine viirusinfektsioonide raviks
BR9608758A (pt) Uso de ribavirina e interferom alfa para o tratamento de hepatite c
PT950138E (pt) Processos de fabrico de appel e materiais para serem usados nos referidos processos
EE03901B1 (et) Elastne vaheriie ja selle kasutamine
DE69930647D1 (de) Struktur-analoga von amin-basen und nucleosiden
PT1212317E (pt) Derivados de indole e sua utilizacao no tratamento de osteoporose entre outras aplicacoes
NO984836D0 (no) Substituerte benzylaminer og deres anvendelse for behandling av depresjon
FI960850A0 (fi) Kinoksaliinien käyttö proteaasi-inhibiittoreihin yhdistettyinä lääkkeeksi AIDS:in ja/tai HIV-tartuntojen hoitamiseksi
NO983402D0 (no) Nukeosidanaloger i kombinasjonsterapi av herpes simplex infeksjoner
DE59814343D1 (de) Flachstrahler mit dielektrisch behinderter entladung und anordnung zur durchführung der elektroden in den entladungsraum
FI964809A0 (fi) En utrustning foer tillverkning av taeckplaot
EP1322319A4 (en) USE OF IL-8 PROTEIN MODULATORS IN THE TREATMENT OF VIRUS INFECTIONS
BR9509986A (pt) Uso de agentes antivirais aminopurina para o tratamento e profilaxia de infecções de vírus de herpes latentes
NO995620D0 (no) Antivirale kombinasjoner inneholdende karbocyklisk nukleosid 1592U89
EE04456B1 (et) Laeva tsentraalne läbiveokanal ja selle kasutamine
ID29586A (id) ((aminoiminometil)amino) alkanakarboksamida-((aminoiminometil)amino) alkanakarboksamida dan aplikasi-aplikasinya dalam terapi
EE200200168A (et) PRV-1-geen ja selle kasutamine
ID16730A (id) Dihidro pirimidina dan penggunaannya
ITCA950008A0 (it) Impiego di combinaqzioni di analoghi di nucleosidi nella terapia delleinfezioni dell'aids.
SE9403566D0 (sv) Gripanordning med steglöst ökad grip och/eller tryckkraftegenskap
SE9500312D0 (sv) Gripanordning med steglöst ökad grip och/eller tryckkraftegenskap
SE9500628D0 (sv) Gripanordning med steglöst ökad grip och/eller tryckkraftegenskap

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20021231

KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20091231

KB4A Valid patent at the end of a year

Effective date: 20101231